Sangamo Therapeutics (SGMO.Q) 주식 개요
임상 단계의 게놈 의학 회사인 상가모 테라퓨틱스는 미국에서 중증 질환으로 고통받는 환자와 가족의 삶을 변화시키는 과학을 의약품으로 전환하는 데 주력하고 있습니다. 자세히 보기
SGMO.Q Community Fair Values
Create NarrativeSee what 39 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Sangamo Therapeutics, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$0.045 |
| 52주 최고가 | US$0.77 |
| 52주 최저가 | US$0.03 |
| 베타 | 1.29 |
| 1개월 변동 | -79.33% |
| 3개월 변동 | -85.36% |
| 1년 변동 | -91.68% |
| 3년 변동 | -96.54% |
| 5년 변동 | -99.62% |
| IPO 이후 변동 | -99.70% |
최근 뉴스 및 업데이트
내러티브 업데이트 • Jun 25
SGMO: Bankruptcy Restructuring Will Set Up Fabry-Focused Recovery Potential
The analyst price target for Sangamo Therapeutics has been cut from $10 to $5 as analysts factor in higher funding and partnership uncertainty related to completing the Fabry biologics license application and progressing the neurology pipeline. What’s in the News for Sangamo Therapeutics Sangamo Therapeutics filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on June 23, 2026, listing assets and liabilities each in the range of US$100 million to US$500 million, with Richards, Layton & Finger, P.A. and Cooley LLP as legal counsel, and MERU, LLC, Raymond James & Associates, Inc., and Kurtzman Carson Consultants LLC d/b/a Verita Global engaged as advisors and claims agent.
내러티브 업데이트 • Jun 05
SGMO: Fabry Filing Progress Will Support Neurology Pipeline Despite Funding Uncertainty
Narrative Update: Sangamo Therapeutics Price Target Revision Analysts have cut their price target on Sangamo Therapeutics from $10 to $5. This reflects concerns about the uncertainty around securing a commercialization partner or sufficient funding to complete the Fabry biologics license application process and continue developing the neurology pipeline, even as the underlying regulatory and clinical thesis for isaralgagene civaparvovec remains in place.Recent updates
내러티브 업데이트 • Jun 25
SGMO: Bankruptcy Restructuring Will Set Up Fabry-Focused Recovery Potential
The analyst price target for Sangamo Therapeutics has been cut from $10 to $5 as analysts factor in higher funding and partnership uncertainty related to completing the Fabry biologics license application and progressing the neurology pipeline. What’s in the News for Sangamo Therapeutics Sangamo Therapeutics filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the District of Delaware on June 23, 2026, listing assets and liabilities each in the range of US$100 million to US$500 million, with Richards, Layton & Finger, P.A. and Cooley LLP as legal counsel, and MERU, LLC, Raymond James & Associates, Inc., and Kurtzman Carson Consultants LLC d/b/a Verita Global engaged as advisors and claims agent.내러티브 업데이트 • Jun 05
SGMO: Fabry Filing Progress Will Support Neurology Pipeline Despite Funding Uncertainty
Narrative Update: Sangamo Therapeutics Price Target Revision Analysts have cut their price target on Sangamo Therapeutics from $10 to $5. This reflects concerns about the uncertainty around securing a commercialization partner or sufficient funding to complete the Fabry biologics license application process and continue developing the neurology pipeline, even as the underlying regulatory and clinical thesis for isaralgagene civaparvovec remains in place.내러티브 업데이트 • Apr 20
SGMO: Fabry Filing Progress Will Offset Going Concern And Liquidity Fears
Analysts have updated their price target on Sangamo Therapeutics to reflect revised assumptions for the discount rate, revenue growth, profit margin and future P/E. The new fair value estimate remains at $1.00, in line with the prior $1.00 target.내러티브 업데이트 • Apr 06
SGMO: Fabry Gene Therapy Filing And Diagnostic Will Drive Future Upside
Analysts have trimmed their price target on Sangamo Therapeutics from $1.25 to $1.00, citing updated assumptions for revenue growth, profit margins and future P/E that have reset expectations for the stock. What's in the News Sangamo reported unaudited impairment charges on long lived assets of US$13,235,000 for the fourth quarter ended December 31, 2025, which affects reported earnings quality for that period (Key Developments).내러티브 업데이트 • Mar 22
SGMO: Fabry Gene Therapy Filing And Kidney Endpoint Will Drive Upside
Analysts have adjusted their price target on Sangamo Therapeutics to $1.25, with the change based on updated views on discount rate, revenue growth, profit margin, and future P/E assumptions, even though the fair value estimate itself remains $1.25. What's in the News Sangamo started a rolling submission of a Biologics License Application to the FDA for isaralgagene civaparvovec (ST-920), an investigational one time gene therapy for adults with Fabry disease, and has submitted the preclinical and clinical modules for review (Key Developments).내러티브 업데이트 • Mar 08
SGMO: Accelerated Approval Pathway On Kidney Data Will Drive Bullish Upside
Analysts have set their price target for Sangamo Therapeutics at $1.25, based on updated assumptions for discount rate, revenue growth, profit margin, and future P/E, while the fair value estimate remains unchanged at $1.25. What's in the News Sangamo reported detailed data from the registrational Phase 1/2 STAAR study of its gene therapy candidate isaralgagene civaparvovec (ST 920) for Fabry disease.내러티브 업데이트 • Feb 22
SGMO: Accelerated Approval On Kidney Function Data Will Drive Bullish Thesis
Analysts have maintained their average price target for Sangamo Therapeutics at $1.25. This reflects minor adjustments to their models, including slightly different assumptions for discount rate, revenue growth, profit margin, and forward P/E, rather than a change in their overall view.내러티브 업데이트 • Feb 07
SGMO: Accelerated Approval Using EGFR Slope Will Support Bullish Outlook
Analysts have nudged their fair value estimate for Sangamo Therapeutics higher to $1.25 from $1.00, citing updated assumptions around revenue growth, profit margins, discount rates and a higher future P/E multiple. What's in the News Sangamo Therapeutics completed a follow on equity offering totaling approximately US$24.8 million, issuing 35,190,292 shares of common stock at US$0.4719 per share and 17,787,033 pre funded warrants at US$0.4619 per warrant (Key Developments).분석 기사 • Feb 03
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Boosted 29% But Its Business Prospects Need A Lift Too
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have had a really impressive month, gaining 29% after a shaky period...
내러티브 업데이트 • Jan 23
SGMO: Accelerated Approval Pathway Will Drive Upside Despite Downgrade Through 2026
Narrative Update Analysts have cut their price target on Sangamo Therapeutics from US$5 to US$1, citing the recent downgrade to Equal Weight and a wait for more clarity on a potential Fabry deal, despite the FDA reaffirming an accelerated approval path and the company extending its cash runway into Q1 2026. Analyst Commentary Recent research paints a mixed picture for Sangamo Therapeutics, with the lower price target and rating downgrade balanced against some supportive clinical and balance sheet signals.내러티브 업데이트 • Jan 09
SGMO: Accelerated Approval Path Using EGFR Slope Will Drive Future Upside
Analysts have trimmed their 12 month price target on Sangamo Therapeutics to US$1 from US$5, citing a wait and see stance on Fabry deal clarity and the current cash runway into Q1 2026, despite the reaffirmed accelerated approval path using eGFR slope. Analyst Commentary Bearish analysts are signaling a more cautious stance on Sangamo Therapeutics after the recent Q3 update, with the sharp cut in the 12 month price target standing out as a key marker of reduced confidence.내러티브 업데이트 • Dec 25
SGMO: Accelerated Approval Pathway And Extended Runway Will Support Upside Through 2026
Analysts have modestly reduced their price target on Sangamo Therapeutics to $1 from $5, citing a more cautious stance as they await greater clarity on potential Fabry partnership developments, despite the extended cash runway and reaffirmed accelerated approval pathway. Analyst Commentary Analysts note that the downgrade and lower price target reflect a shift toward a more balanced risk reward profile, with recent catalysts prompting both supportive and cautious views on Sangamo Therapeutics.내러티브 업데이트 • Dec 11
SGMO: Accelerated Approval Pathway Is Expected To Drive Upside Through 2026
Analysts have lowered their price target on Sangamo Therapeutics from $5.00 to $1.00 per share, citing a more cautious stance as they await greater clarity on a potential Fabry partnership, despite an extended cash runway and a reaffirmed accelerated approval path. Analyst Commentary Analysts are reassessing Sangamo Therapeutics with a more balanced view, emphasizing both the company’s de-risked regulatory path and the uncertainties that could weigh on execution and valuation.내러티브 업데이트 • Nov 27
SGMO: FDA Accelerated Pathway Will Extend Bullish Momentum Into 2026
Analysts have lowered Sangamo Therapeutics’ price target from $5 to $1, citing uncertainty around future partnership deals. This is despite recent regulatory updates and an extended cash runway.분석 기사 • Nov 23
Revenues Working Against Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Share Price Following 33% Dive
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have had a horrible month, losing 33% after a relatively good period...내러티브 업데이트 • Nov 08
SGMO: FDA Approval Path Will Drive Bullish Outlook Into 2026
Analysts have lowered their price target for Sangamo Therapeutics from $5 to $1. They cited a cautious outlook, pending greater clarity on a Fabry collaboration and updated guidance following the company's latest quarterly report.분석 기사 • Oct 07
There's No Escaping Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Muted Revenues Despite A 28% Share Price Rise
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have continued their recent momentum with a 28% gain in the last...분석 기사 • Sep 23
Companies Like Sangamo Therapeutics (NASDAQ:SGMO) Are In A Position To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...내러티브 업데이트 • Sep 21
FDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects
The sharp increase in Sangamo Therapeutics' consensus analyst price target is primarily driven by a significantly higher future P/E expectation, indicating greater anticipated earnings growth or improved sentiment, with the fair value rising from $2.62 to $4.10. What's in the News CFO Prathyusha Duraibabu resigned, effective October 1, to join a private AI company; no disagreements cited in her departure.내러티브 업데이트 • Sep 06
FDA Approval In 2026 Will Extend Fabry Gene Therapy Prospects
Sangamo Therapeutics' fair value has been revised downward, primarily reflecting meaningful declines in both its forward P/E multiple and net profit margin, resulting in a lower consensus price target of $2.62. What's in the News Sangamo presented detailed data from the registrational Phase 1/2 STAAR study of isaralgagene civaparvovec (ST-920), its investigational gene therapy for adults with Fabry disease, showing a positive mean annualized eGFR slope of 1.965 mL/min/1.73m2/year in all patients followed at least 12 months.분석 기사 • Jul 24
Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Those holding Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares would be relieved that the share price has rebounded...
새로운 내러티브 • Apr 01
Neurology IND And Fabry Agreements Will Transform Treatment
Strategic partnerships and collaborations position Sangamo as a key player, enhancing revenue potential through non-dilutive capital and licensing agreements.분석 기사 • Mar 04
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
To the annoyance of some shareholders, Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares are down a considerable 25% in...분석 기사 • Dec 08
Investors Don't See Light At End Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Tunnel And Push Stock Down 30%
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have retraced a considerable 30% in the last month, reversing a fair...분석 기사 • Nov 20
Analysts Just Made A Massive Upgrade To Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Forecasts
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders will have a reason to smile today, with the analysts making...분석 기사 • Oct 23
What Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 26% Share Price Gain Is Not Telling You
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have continued their recent momentum with a 26% gain in the last...Seeking Alpha • Oct 21
Sangamo Follow-Up: Giro-Vec And STAC-BBB? Check. Isa-Vec... Trifecta Soon?
Summary Sangamo Therapeutics, Inc.'s stock surged after positive updates on two lead assets, giro-vec and STAC-BBB, with potential for significant milestone payments and partnerships. The upcoming isa-vec deal could be transformative, potentially securing Sangamo's financial stability and pushing its valuation towards $1 billion. Despite recent gains, high volatility and financial risks make SGMO a speculative investment, suitable only for risk-tolerant investors. Key risks include potential setbacks in giro-vec and isa-vec developments, which could impact Sangamo's cash flow and overall valuation. Read the full article on Seeking Alpha분석 기사 • Aug 03
There's Reason For Concern Over Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Massive 171% Price Jump
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders would be excited to see that the share price has had a great...Seeking Alpha • Jul 23
Sangamo Therapeutics: A Bust Or Billion Dollar Valuation In The Remaking
Summary Sangamo Therapeutics, Inc. is almost out of cash, and as such, at risk of bankruptcy. Therefore, investing in this company is not a good idea for most investors. 3 of its assets have updates coming over the next 1–6 months that could realistically bring in a combination of ~$1B of cash & milestones over the next 12–18 months. Due to its history of burning cash and not being able to get a drug approved yet, Sangamo Therapeutics's stock price closed Monday, 07/22/24 at $0.395/s or a valuation of ~$82M. Below, I will discuss why I think the company is going to make it and possibly deliver 5-10x over the next 6–12 months. Read the full article on Seeking Alpha분석 기사 • Jun 19
Lacklustre Performance Is Driving Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) 35% Price Drop
Unfortunately for some shareholders, the Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) share price has dived 35% in the...분석 기사 • May 29
We Think Shareholders May Want To Consider A Review Of Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) CEO Compensation Package
Key Insights Sangamo Therapeutics' Annual General Meeting to take place on 4th of June CEO Sandy Macrae's total...분석 기사 • May 14
This Just In: Analysts Are Boosting Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Outlook for This Year
Shareholders in Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) may be thrilled to learn that the analysts have just...분석 기사 • Mar 23
Little Excitement Around Sangamo Therapeutics, Inc.'s (NASDAQ:SGMO) Revenues As Shares Take 36% Pounding
Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shares have retraced a considerable 36% in the last month, reversing a fair...분석 기사 • Mar 16
Analysts Have Just Cut Their Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Revenue Estimates By 24%
Today is shaping up negative for Sangamo Therapeutics, Inc. ( NASDAQ:SGMO ) shareholders, with the analysts delivering...주주 수익률
| SGMO.Q | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | -74.2% | 7.5% | -2.5% |
| 1Y | -91.7% | 40.9% | 19.0% |
수익률 대 산업: SGMO.Q은 지난 1년 동안 40.9%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: SGMO.Q은 지난 1년 동안 19%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| SGMO.Q volatility | |
|---|---|
| SGMO.Q Average Weekly Movement | 33.1% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
안정적인 주가: SGMO.Q의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.
시간에 따른 변동성: SGMO.Q의 주간 변동성은 지난 1년간 20%에서 33%로 증가했습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1995 | 142 | Sandy Macrae | www.sangamo.com |
임상 단계의 게놈 의학 회사인 상가모 테라퓨틱스(Sangamo Therapeutics, Inc.)는 미국에서 중증 질환으로 고통받는 환자와 가족의 삶을 변화시키는 의약품으로 과학을 전환하는 데 주력하고 있습니다. 이 회사의 임상 단계 제품 후보로는 파브리병 치료를 위한 임상 1/2상 연구 중인 유전자 치료 제품 후보인 ST-920, 만성 신경병증성 통증 및 프리온 질환을 위한 소섬유 신경병증, 신장 이식 환자를 대상으로 연구용 유전자 변형 세포 치료제 TX200의 안전성 및 내약성을 평가하는 임상 1/2상 시험이 있습니다.중등도에서 중증 A형 혈우병 치료를 위한 임상 3상 시험 중인 유전자 치료 제품 후보인 SB-525; 중등도 또는 중증 A형 혈우병 성인 남성을 대상으로 지록토코진 피텔파보벡 유전자 치료의 임상 효능과 안전성을 평가하기 위한 임상 3상 연구인 지록토코진 피텔파보벡; 중등도 또는 중증 A형 혈우병 환자를 대상으로 한 임상 3상 시험인 지로토코진 피텔파보벡. 상가모 테라퓨틱스는 제넨텍, 아스텔라스 진 테라피즈, 일라이 릴리 앤 컴퍼니와 캡시드 전달 라이선스 계약, 알렉시온 파마슈티컬스, 루게릭병 및 전측두엽변성, 다케다, 헌팅턴병, 식물 농업 및 연구 시약 등 기타 분야에서 협력 및 전략적 제휴를 맺고 있으며 코레바 애그리사이언스, 오픈 모노클로날 테크놀로지와 함께 형질전환 동물 및 세포주 엔지니어링 생산에 협력하고 있습니다.
Sangamo Therapeutics, Inc. 기초 지표 요약
| SGMO.Q 기초 통계 | |
|---|---|
| 시가총액 | US$18.64m |
| 순이익 (TTM) | -US$123.33m |
| 매출 (TTM) | US$34.56m |
0.5x
주가매출비율(P/S)-0.2x
주가수익비율(P/E)SGMO.Q는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| SGMO.Q 손익계산서 (TTM) | |
|---|---|
| 매출 | US$34.56m |
| 매출원가 | US$113.23m |
| 총이익 | -US$78.68m |
| 기타 비용 | US$44.65m |
| 순이익 | -US$123.33m |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -0.30 |
| 총이익률 | -227.67% |
| 순이익률 | -356.89% |
| 부채/자본 비율 | 0% |
SGMO.Q의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/06/28 04:48 |
| 종가 | 2026/06/26 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Sangamo Therapeutics, Inc.는 16명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Gregory Harrison | BofA Global Research |
| Douglas Buchanan | Brean Capital Historical (Janney Montgomery) |
| John Newman | Citizens JMP Securities, LLC |